News stories about MAXIMUS (NYSE:MMS) have trended somewhat positive on Thursday, according to Accern Sentiment. The research firm ranks the sentiment of media coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. MAXIMUS earned a coverage optimism score of 0.09 on Accern’s scale. Accern also assigned news coverage about the health services provider an impact score of 45.5686076865772 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Here are some of the news articles that may have effected Accern Sentiment’s analysis:
MAXIMUS (MMS) opened at $70.09 on Thursday. MAXIMUS has a fifty-two week low of $51.74 and a fifty-two week high of $72.54. The stock has a market cap of $4,630.00, a P/E ratio of 22.11, a price-to-earnings-growth ratio of 2.67 and a beta of 1.34.
The company also recently declared a quarterly dividend, which will be paid on Wednesday, February 28th. Shareholders of record on Thursday, February 15th will be issued a dividend of $0.045 per share. This represents a $0.18 annualized dividend and a yield of 0.26%. MAXIMUS’s payout ratio is 5.68%.
A number of research firms recently commented on MMS. Canaccord Genuity reaffirmed a “buy” rating on shares of MAXIMUS in a research report on Wednesday, December 27th. Zacks Investment Research upgraded shares of MAXIMUS from a “hold” rating to a “buy” rating and set a $73.00 price objective on the stock in a research note on Wednesday, October 4th. Two analysts have rated the stock with a sell rating, five have issued a hold rating and one has given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of $64.33.
In other news, General Counsel David Francis sold 3,900 shares of MAXIMUS stock in a transaction on Monday, November 13th. The shares were sold at an average price of $63.97, for a total value of $249,483.00. Following the completion of the sale, the general counsel now owns 15,090 shares in the company, valued at approximately $965,307.30. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Russell A. Beliveau sold 1,000 shares of MAXIMUS stock in a transaction on Tuesday, January 2nd. The shares were sold at an average price of $71.73, for a total transaction of $71,730.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 71,417 shares of company stock valued at $4,902,785. Company insiders own 3.10% of the company’s stock.
WARNING: This piece was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece on another site, it was copied illegally and republished in violation of U.S. & international copyright law. The correct version of this piece can be viewed at https://www.dispatchtribunal.com/2018/01/11/maximus-mms-receiving-somewhat-favorable-media-coverage-study-shows.html.
MAXIMUS Company Profile
MAXIMUS, Inc provides business process services (BPS) to government health and human services agencies. The Company operates through three segments: U.S. Federal Services, Health Services and Human Services. The U.S. Federal Services segment provides BPS and program management for large government programs, independent health review and appeals services for both the United States Federal Government, and state-based programs and technology solutions for civilian federal programs.
Receive News & Ratings for MAXIMUS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MAXIMUS and related companies with MarketBeat.com's FREE daily email newsletter.